Presented in part at the 41st annual meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, Dec. 8–12, 2002. From the UCLA Department of Psychiatry and Biobehavioral Sciences; the Department of Psychiatry, VA Greater Los Angeles Healthcare System, West Los Angeles Healthcare Center, Los Angeles; and the Ahmanson-Lovelace Brain Mapping Center, UCLA School of Medicine, Los Angeles. Address correspondence and reprint requests to Dr. Altshuler, 300 UCLA Medical Plaza, Suite 1544, Box 957057, Los Angeles, CA 90095-7057; firstname.lastname@example.org (e-mail). Support for this study was received from The Stanley Medical Research Institute, the National Alliance for Research on Schizophrenia and Depression, the Brain Mapping Medical Research Organization, the Brain Mapping Support Foundation, Pierson-Lovelace Foundation, Ahmanson Foundation, Tamkin Foundation, Jennifer Jones-Simon Foundation, Capital Group Companies Charitable Foundation, Robson Family, Northstar Fund, and grants from NIMH (K24 MH-01848), the National Institute on Drug Abuse (DA-13054), and the National Center for Research Resources (RR-12169, RR-13642, and RR-08655). The authors thank Joaquin Fuster, M.D., Ph.D., for consultation during the development of this manuscript.